MAP2K1 and epilepsy: A recent clinical study by Pierpont et al. [6] reported a higher rate of CFC patients affected by epilepsy than in the previously published literature: seizures of various type occurred in 57% of individuals with BRAF pathogenic variants, 61% of patients with MAP2K1 pathogenic variants and 30% of subjects with MAP2K2 pathogenic variants.